4//SEC Filing
Chiang Hsiangyi 4
Accession 0000899243-23-001590
CIK 0001623715other
Filed
Jan 10, 7:00 PM ET
Accepted
Jan 11, 4:13 PM ET
Size
12.0 KB
Accession
0000899243-23-001590
Insider Transaction Report
Form 4
Chiang Hsiangyi
Senior Vice President Finance
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-01-11−91,500→ 0 totalExercise: $15.45Exp: 2032-11-07→ Common Stock (91,500 underlying) - Disposition from Tender
Common Stock
2023-01-11$36.00/sh−26,538$955,368→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-11−86,206→ 0 totalExercise: $4.20Exp: 2031-02-04→ Common Stock (86,206 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-11−23,500→ 0 totalExercise: $22.76Exp: 2031-11-16→ Common Stock (23,500 underlying)
Footnotes (1)
- [F1]On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option.
Documents
Issuer
Imago BioSciences, Inc.
CIK 0001623715
Entity typeother
Related Parties
1- filerCIK 0001945318
Filing Metadata
- Form type
- 4
- Filed
- Jan 10, 7:00 PM ET
- Accepted
- Jan 11, 4:13 PM ET
- Size
- 12.0 KB